Damora Therapeutics annual stock-based compensation
2020
2021
2022
2023
2024
2025
Damora Therapeutics Stock-Based Compensation Growth & History (DMRA)
Damora Therapeutics's stock-based compensation was $998,000 for fiscal 2025.
View full Damora Therapeutics company overviewDamora Therapeutics annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $998,000 | −$2.2M | −69.19% |
| 2024 | 2024-12-31 | $3.2M | −$2.2M | −40.32% |
| 2023 | 2023-12-31 | $5.4M | −$144,000 | −2.58% |
| 2022 | 2022-12-31 | $5.6M | $1.1M | +24.35% |
| 2021 | 2021-12-31 | $4.5M | $3.5M | +356.21% |
| 2020 | 2020-12-31 | $982,000 | — | — |
Damora Therapeutics quarterly stock-based compensation
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $6.1M | $6.0M | +3472.09% |
| Q1 2026 | 2026-03-31 | $3.1M | $3.0M | +1650.84% |
| Q4 2025 | 2025-12-31 | $483,000 | $175,000 | +56.82% |
| Q3 2025 | 2025-09-30 | $164,000 | −$517,000 | −75.92% |
| Q2 2025 | 2025-06-30 | $172,000 | −$719,000 | −80.70% |
| Q1 2025 | 2025-03-31 | $179,000 | −$1.2M | −86.83% |
| Q4 2024 | 2024-12-31 | $308,000 | −$782,000 | −71.74% |
| Q3 2024 | 2024-09-30 | $681,000 | −$783,000 | −53.48% |
| Q2 2024 | 2024-06-30 | $891,000 | −$548,000 | −38.08% |
| Q1 2024 | 2024-03-31 | $1.4M | −$75,000 | −5.23% |
| Q4 2023 | 2023-12-31 | $1.1M | −$259,000 | −19.20% |
| Q3 2023 | 2023-09-30 | $1.5M | $65,000 | +4.65% |
| Q2 2023 | 2023-06-30 | $1.4M | $20,000 | +1.41% |
| Q1 2023 | 2023-03-31 | $1.4M | $30,000 | +2.14% |
| Q4 2022 | 2022-12-31 | $1.3M | $106,000 | +8.53% |
| Q3 2022 | 2022-09-30 | $1.4M | $180,000 | +14.77% |
| Q2 2022 | 2022-06-30 | $1.4M | $432,000 | +43.77% |
| Q1 2022 | 2022-03-31 | $1.4M | $373,000 | +36.18% |
| Q4 2021 | 2021-12-31 | $1.2M | $768,000 | +161.68% |
| Q3 2021 | 2021-09-30 | $1.2M | $1.1M | +816.54% |
| Q2 2021 | 2021-06-30 | $987,000 | $613,000 | +163.90% |
| Q1 2021 | 2021-03-31 | $1.0M | $1.0M | — |
| Q4 2020 | 2020-12-31 | $475,000 | — | — |
| Q3 2020 | 2020-09-30 | $133,000 | — | — |
| Q2 2020 | 2020-06-30 | $374,000 | — | — |
| Q1 2020 | 2020-03-31 | $0 | — | — |
Damora Therapeutics stock-based compensation trends
Over the last five fiscal years, Damora Therapeutics's stock-based compensation increased from $982,000 to $998,000, a change of $16,000. The latest reported quarter, Q2 2026, shows $6.1M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Damora Therapeutics source filings ↗